Evidence map›Paper›PMID 28143894›Full record

ArticleJournal of lipid research2017

Analysis of glycero-lysophospholipids in gastric cancerous ascites.

Shigenobu Emoto, Makoto Kurano, Kuniyuki Kano, Keisuke Matsusaki, Hiroharu Yamashita, Masako Nishikawa, Koji Igarashi, Hitoshi Ikeda, Junken Aoki, Joji Kitayama and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of lipid research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Shigenobu EmotoDepartment of Surgical Oncology, University of Tokyo, Tokyo, Japan.
Makoto KuranoDepartments of Clinical Laboratory Medicine and Gastrointestinal Surgery, University of Tokyo, Tokyo, Japan; CREST, Japan Science and Technology Corporation (JST).
Kuniyuki KanoCREST, Japan Science and Technology Corporation (JST); Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan.
Keisuke MatsusakiKanamecho Hospital, Tokyo, Japan.
Hiroharu YamashitaGraduate School of Medicine, University of Tokyo, Tokyo, Japan.
Masako NishikawaDepartments of Clinical Laboratory Medicine and Gastrointestinal Surgery, University of Tokyo, Tokyo, Japan; CREST, Japan Science and Technology Corporation (JST).
Koji IgarashiBioscience Division, TOSOH Corporation, Kanagawa, Japan.
Hitoshi IkedaDepartments of Clinical Laboratory Medicine and Gastrointestinal Surgery, University of Tokyo, Tokyo, Japan; CREST, Japan Science and Technology Corporation (JST).
Junken AokiCREST, Japan Science and Technology Corporation (JST); Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan.
Joji KitayamaDepartment of Surgical Oncology, University of Tokyo, Tokyo, Japan; Department of Gastrointestinal Surgery, Jichi Medical University, Tochigi, Japan.
Yutaka YatomiDepartments of Clinical Laboratory Medicine and Gastrointestinal Surgery, University of Tokyo, Tokyo, Japan; CREST, Japan Science and Technology Corporation (JST). Electronic address: yatoyuta-tky@umin.ac.jp.
The University of Tokyo · JPJapan Science and Technology Agency · JPJichi Medical University · JPTohoku University · JPTosoh (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysophosphatidic acid (LysoPA) has been proposed to be involved in the pathogenesis of various cancers. Moreover, glycero-lysophospholipids (glycero-LysoPLs) other than LysoPA are now emerging as novel lipid mediators. Therefore, we aimed to elucidate the possible involvement of glycero-LysoPLs in the pathogenesis of gastric cancer by measuring glycero-LysoPLs, autotaxin (ATX), and phosphatidylserine-specific phospholipase A1 (PS-PLA

Indexed as

AnimalsAscitesFemaleFibrosisHumansLysophospholipase DLysophospholipidsMaleMicePhospholipases A1Phosphoric Diester HydrolasesStomach Neoplasmslysophosphatidic acidlysophosphatidylglycerollysophosphatidylserineLysophospholipase DLysophospholipidsPhospholipases A1Phosphoric Diester HydrolasesPLA1A protein, humanascitesautotaxincirrhosisgastric cancer

Identifiers

PMID28143894
PMCPMC5392751
OpenAlexW2584164012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.